Breaking News: Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19 | Financial Buzz

Breaking News: Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL biology joint venture partner NLC Pharma, Ltd., announced today that it will host a Key Opinion Leader (KOL) webinar entitled Tollovir™: a Potential Treatment for Covid-19 on December 22, 2021 at 12:00pm ET.

This webinar will feature presentations from KOLs Yossef Av-Gay, Ph.D., from the University of British Columbia, and David Greenberg, MD, Faculty Member of Health Sciences of the Ben-Gurion University of the Negev.

• Dr. Av-Gay will discuss the mechanics of SARS-CoV-2 viral replication, 3CL protease biology and the relevant benefits of targeting 3CL protease with respect to viral replication, NEMO cleavage inhibition and its role potentially downregulating innate immune response to infection.

• Dr. Greenberg will present a review of SARS-CoV-2 virus biology and what the relevant therapeutic targets are for antiviral intervention, which interventions are being evaluated, and what occurs in the state of hyper-inflammation and cytokine storm that occurs.

A presentation by Dr. Dorit Arad, NLC Pharma, JV partner with Todos Medical, will discuss 3CL protease inhibition and the various medicines targeting it. Todos will examine the competitive landscape referencing past studies as well discuss what is upcoming, including Todos Medical’s Tollovir™ 3CL protease inhibitor oral antiviral Phase II Covid-19 trial results in hospitalized patents, expected to be released to the public in December 2021, or early January 2022.

A question and answer session will follow. To register for the event, please click here.

David Greenberg, MD is an Associated Professor at the Faculty of Health Sciences of the Ben-Gurion University of the Negev. He is serving as the Chairman of the Israeli Clinical Pediatric Society. Dr. Greenberg is a member of the COVID vaccines advisory team for the Ministry of Health in Israel.

Dr. Greenberg obtained his MD from Ben-Gurion University of the Negev in Beer-Sheva, Israel in 1991, was boarded in Pediatrics in 1996, and did his fellowship in Pediatric Infectious Diseases at “The Children’s Hospital” in Vancouver from 1997 to 1999. He was boarded in Infectious Diseases in Israel in 2000. He joined the Department of Pediatrics and the Pediatric Infectious Disease Unit of Soroka University Medical Center as a pediatrician and a senior consultant in Pediatric Infectious Diseases in 1999. In collaboration with various researchers from several universities worldwide, Dr. Greenberg was a member World Health Organization Pneumonia Vaccine Trial Investigators’ Group and of the Pneumococcal Molecular Epidemiology Network (PMEN).

Dr. Greenberg’s research activities focus on respiratory infections such as pneumonia and otitis media, on vaccines such as the pneumococcal conjugated vaccines and on invasive infections such as bacteremia and meningitis mostly caused by Streptococcus pneumoniae. He is particularly interested in epidemiology, molecular epidemiology and carriage of S. pneumoniae as well as in and the spread of antibiotic resistant pneumococci in the community. He is author or co-author of over 80 publications.

Yossef Av-Gay, PhD is a University of British Columbia (UBC) professor in the Division of Infectious Diseases, Faculty of Medicine and is an associate member of the Department of Microbiology and Immunology, Faculty of Sciences. He is also an associate member of the department of microbiology and immunology and holds an adjunct professorship at the medical school of Ben Gurion University of the Negev, Israel.

Prof. Av-Gay received his BSc in Biology, MSc in Microbiology, and PhD in Microbial Genetics – all from Tel Aviv University, Tel Aviv, Israel, and advanced training at John Innes Institute, Norwich, UK, Albert Einstein Collage of Medicine, New York and UBC Microbiology.

Prof. Av-Gay authored over 100 peer review scientific publications, review articles, book chapters and 15 patents. Prof. Av-Gay served as an editor for the Journal of Biological Chemistry (2010-2015), and on scientific advisory boards of several biotechnology companies. Prof. Av-Gay is a member of the scientific review panels of the Canadian Institute of Health Research Microbiology and Infectious Disease (2009-2016) and Foundation and Project Grants (2016-), the French Agence Nationale de la Recherche, Innovative Medicine Innovations, The UK Wellcome Trust, US National Institute of Health, and the European Commission FP6, FP7 and Horizon 2020 programs.

Concurrent with this announcement, the Company, along with NLC Pharma, have agreed to extend the closing date for the formation of their new joint venture 3CL Sciences (60% owned by Todos / 40% owned by NLC Pharma) to December 31, 2021 in order to allow for the completion of legal due diligence by both companies.

Sponsored Content Release. Click for Full Disclosure

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: